CDK12 and posterior cortical atrophy: For instance, a PCa patient with a base substitution (c.4211C > G) in BRCA2 showed a response to radiotherapy and androgen deprivation therapy (ADT) in a Chinese cohort study [80], while patients with CDK12 mutations did not respond well to hormonal therapy, PARPi or taxanes but showed positive (and occasionally durable) responses to PD-1 inhibition [81,82].